Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;20(3):361-369.
doi: 10.5217/ir.2021.00126. Epub 2022 Mar 15.

Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn's disease: two complementary tests

José María Paredes  1 , Tomás Ripollés  2 , Ángela Algarra  1 , Rafael Diaz  1 , Nadia Moreno  1 , Patricia Latorre  1 , María Jesús Martínez  2 , Pilar Llopis  3 , Antonio López  1 , Eduardo Moreno-Osset  1
Affiliations

Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn's disease: two complementary tests

José María Paredes et al. Intest Res. 2022 Jul.

Abstract

Background/aims: Tight control of inflammation and adjustment of treatment if activity persists is the current strategy for the management of Crohn's disease (CD). The usefulness of fecal calprotectin (FC) in isolated involvement of the small intestine in CD is controversial. To assess the usefulness of FC to determine the inflammatory activity detected by intestinal ultrasonography (IUS) in ileal CD.

Methods: Patients with exclusively ileal involvement CD who underwent IUS and an FC were prospectively included. Simple ultrasound index was used to determine inflammatory activity. The usual statistical tests for comparison of diagnostic techniques were used.

Results: One hundred and five patients were included, IUS showed inflammatory activity in 59% of patients and complications in 18.1%. FC showed a significant correlation with IUS in the weak range (Spearman coefficient r=0.502; P<0.001); the area under the receiver operating characteristic curve was 0.79 (95% confidence interval, 0.70-0.88; P<0.001). The FC value that best reflected the activity in IUS was 100 μg/g with sensitivity, specificity, and positive and negative predictive values of 73.0%, 71.4%, 79.3% and 63.8%, respectively. There were no differences in FC concentration between patients with or without transmural complications. The addition of serum C-reactive protein to FC did not improve the ability to assess IUS activity.

Conclusions: FC has a significant correlation with IUS to monitor ileal CD activity. This correlation is weak and it does not allow assessing the presence of CD complications. Both tests should be used in conjunction for tight control of ileal CD. More studies on noninvasive tests in this location are needed.

Keywords: Crohn disease; Fecal calprotectin; Intestinal ultrasonography; Tight control.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1.
Fig. 1.
Flowchart showing the number of patients entering the study. IUS, intestinal ultrasonography.
Fig. 2.
Fig. 2.
Fecal calprotectin receiver operating characteristic curve for assess inflammatory activity in intestinal ultrasonography of ileal Crohn´s disease. AUC, area under the receiver operating characteristic curve.
Fig. 3.
Fig. 3.
Correlation between fecal calprotectin and different ultrasound variables. (A) Correlation between simple ultrasound score and fecal calprotectin concentration. (B) Linear correlation between the wall thickness and fecal calprotectin concentration (95% confidence interval, CI).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2019;68:423–433. - PubMed
    1. Gonczi L, Bessissow T, Lakatos PL. Disease monitoring strategies in inflammatory bowel diseases: what do we mean by “tight control”? World J Gastroenterol. 2019;25:6172–6189. - PMC - PubMed
    1. Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther. 2016;43:317–333. - PubMed
    1. Allocca M, Danese S, Laurent V, Peyrin-Biroulet L. Use of cross-sectional imaging for tight monitoring of inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020;18:1309–1323. - PubMed
    1. D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224. - PubMed